A prolactin-secreting pituitary tumour is the most frequent cause of hyperprolactinaemia that
commonly occurs in clinical practice. Prolactinomas occur more frequently in women than in …

Objectives Prolactin (PRL)-secreting macroadenomas usually measure between 10 and 40
mm. Giant (adenoma size≥ 40 mm) PRL-tumors are not common, and larger prolactinomas …

The authors present an update on the various treatment modalities and discuss
management strategies for prolactinomas. Prolactinomas are the most common type of …

Prevalence and incidence of prolactinomas are approximately 50 per 100,000 and 3–5 new
cases/100,000/year. The pathophysiological mechanism of hyperprolactinemia-induced …

Dopamine agonists such as bromocriptine and cabergoline are the predominant treatment
drugs for prolactinoma by inhibiting prolactin secretion and shrinking tumor size. However …

Abstract Cabergoline (CAB), a new, potent, and long-lasting PRL-lowering agent, was
shown to be effective in tumoral hyperprolactinemia. The aim of this study was to investigate …

Objective To investigate the initial and long-term remission rates, factors related to
remission, secondary treatments, and outcomes for patients with prolactinoma who …

Background Surgical resection of prolactinomas resistant to dopamine agonists is frequently
incomplete due to fibrotic changes of the tumour under pharmacological therapy. In order to …

Background For prolactinoma patients, dopamine agonists (DAs) are indicated as the first-
line treatment and surgery is an adjunctive choice. However, with the development of …

Prolactinomas are benign, sporadic pituitary tumours that typically present with
amenorrhoea and galactorrhoea in women, and hypogonadism and space-occupying …